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Background
Acute musculoskeletal painful conditions are common problems presenting to the emergency department. In moderate and severe pain, early analgesic treatment is effective in reducing suffering, promoting early discharge and early return to work. [1] [2] [3] Ketorolac has been the major injectable analgesic used in acute pain in our department for some time. In our experience, it was effective. However, being a nonsteroidal anti-inflammatory drug (NSAID), we worry about its important potential risks of hypersensitivity reactions and renal, hepatic and gastrointestinal side effects.
Tramadol was recently introduced to our department as an injectable analgesic. It achieves analgesia by two mechanisms: an opioid effect and an enhancement of serotoninergic and adrenergic pathways.
This study aimed to compare the efficacy, acceptance and side effects of intramuscular tramadol and ketorolac in combination with oral paracetamol in the emergency setting. This may affect our prescribing preference and avoid the major adverse reactions of the NSAIDs.
Materials and methods
This was a prospective randomised double-blinded control study (Figure 1 ). Subjects were randomised by block randomisation, with envelops drawn randomly from preset equal number in the two groups. Patients were blinded to the treatment they received. They were asked to complete the questionnaire before they 17 Keywords: Analgesia, ketorolac tromethamine, opioid analgesics received treatment. A clinically independent specialist in the observation room would perform the post injection assessment.
Patients of both sexes from 18 to 65 years of age, with moderate to severe acute musculoskeletal pain (irrespective of trauma history) and also acute arthritis (including gout) presenting within 72 hours of onset were recruited. Patients functionally affected by other medical or surgical conditions, currently on psychiatric medication, with alcohol or opioid dependence, during pregnancy, with known hypersensitivity to paracetamol, NSAID or opioid, with contraindications to NSAIDs or contraindications to opioid/tramadol, patients with neurological deficit, bone fracture or active malignancy were excluded. Subjects included were randomised to receive intramuscular tramadol 100 mg with oral paracetamol 500 mg or intramuscular ketorolac 30 mg with oral paracetamol 500 mg accordingly.
The sample size (n=34 in each group) was calculated with effect size 3.38. 4 The calculated standardised effect size was 0.8, with alpha 0.05 and power 0.90, we can look up in a table and find out the required sample size.
The primary end-point of the study was pain control. It was assessed by a self-completed questionnaire with a visual analogue scale (VAS) before injection and 60 minutes after injection of either drug plus oral paracetamol. The VAS we used was a 10-unit horizontal straight line with each unit equal to 1.5 cm, whereas, 0 represented no pain and 10 represented maximal pain.
The secondary end-points were complications and the satisfaction score measured from 0 to 100 points. The post-treatment VAS, satisfaction score and side effects were assessed and recorded by a clinically independent Senior Medical Officer doing the observation room duty. The blood pressure, pulse rate, oxygen saturation, and rescue analgesics required after the first hour were recorded.
The difference in the VAS improvement between the two groups and vital sign parameters were analysed by the unpaired t-test. A p-value less than 0.05 was considered as statistically significant. Side effects were analysed with Fisher's exact test and Chi-square test.
All the statistical calculation employed the online engine SISA (Simple Interactive Statistical Analysis).
Results
Seventy-eight patients were recruited between 21 June 2005 and 21 September 2005, with equal number of subjects in each group. The two groups were comparable in sex, age and diagnosis. The subjects' characteristics are shown in the Table 1. The majority Table 2 . Analysis result of the difference in visual analogue scale (VAS) improvement, satisfaction score between the tramadol and ketorolac groups and the change in physiological parameters (blood pressure, heart rate and capillary oxygen saturation) before and 60 minutes after the injection of the respective drug (52) suffered from back pain (66.7%), with 28 in the tramadol group and 24 in the ketorolac group, followed by ankle and foot pain (11.5%). There was a statistically significant difference in improvement of VAS score between the two groups, with the tramadol group being better. The mean pre-treatment VAS for the tramadol group was 7.39 with a reduction of 3.12 (42.2%) after treatment, while that for the ketorolac group was 6.72 with an improvement of 2.24 (33.3%) after treatment. There was no significant difference for the initial VAS between the two groups ( Table 1) . The difference in VAS improvement for the two groups was 0.88 (P=0.01) ( Table 2 ). There were no significant differences in satisfaction score and admission rate.
Paired parameter (P1 vs P2) Absolute value (P1/P2) Mean difference (P1-P2) (95% CI) P-value
Nineteen patients (48.7%) in the tramadol group and 17 patients (43.6%) in the ketorolac group experienced side effects. The number of patients in the two groups who experienced and reported side effects was not statistically significant (Chi-square test, P=0.206). Dry mouth was the commonest, with 13 patients (33.3%) in the tramadol group and 12 patients (30.8%) in the ketorolac group. No major life-threatening effect occurred. However, significantly more patients experienced nausea in the tramadol group than in the ketorolac group (6 versus 1, P<0.05) ( Table 3 ).
In both the tramadol and ketorolac groups, there was a slight drop in the mean systolic and diastolic blood pressure, which was not clinically or statistically significant. The mean pulse rate dropped in both groups, which were statistically but not clinically significant for both groups. There was a statistically significant drop in mean oxygen saturation (from 99% to 98%) in the tramadol group, but was not clinical significant.
Six patients required rescue drugs. Two in the tramadol group and three in the ketorolac group required further analgesics (P=0.321) and one in the tramadol group required medication for dizziness (P=0.50). Two patients in the tramadol group and one patient in the ketorolac group were admitted to the orthopaedic department due to severe persistent low back pain (P=0.38).
Discussion
Acute musculoskeletal pain presents commonly to emergency departments. The choice of injectable analgesics has been narrow, namely non-steroidal antiinflammatory drug and sometimes, narcotics in selected patients and conditions.
Ketorolac tromethamine is a member of non-steroidal anti-inflammatory drugs, and has a rapid onset of action of 30 minutes for the intramuscular route, with peak effect at 1 to 2 hours. Like other NSAIDs, it has the potential risks of hypersensitivity reactions, nephotoxicity, hepatotoxicity and gastrointestinal bleeding/ulceration after repeated use. NSAID given intramuscularly may also be very painful and associated with severe local complications. A study by Chung showed that the use of injectable NSAID in local accident and emergency department practice was excessive. 5 He suggested stringent justifications for its intramuscular administration.
The recent introduction of tramadol in our department pr ovided a promising alternative. Tramadol hydrochloride is a synthetic analogue of codeine that has low affinity for the mu-opiate receptors. It has been claimed to be safer with few opioid side effects: notably, respiratory depression, constipation and addiction potential. It has a rapid onset of action by intramuscular injection, with maximum effect within 15 to 30 minutes and duration of action lasting 3 to 6 hours. Siu and Chung found that tramadol was a safe drug in the emergency setting with few and insignificant side effects. 4 Its efficacy as compared with other analgesics required further studies.
Two studies compared the analgesic efficacy of ketorolac and tramadol. Both studies were conducted by anaesthetists in patients undergoing abdominal surgery. Ollé Fortuny et al showed that during the first 12 hours following surgery, a 100 mg dose of tramadol provided more effective pain relief than 30 mg of ketorolac, each administrated intravenously every 6 hours. However, intravenous tramadol was associated with a higher incidence of postoperative vomiting (38%). 6 In Putland and McCluskey's study, patients who received tramadol had less pain in the recovery room and at discharge from the day-surgery unit and required less rescue analgesia with morphine than patients who received ketorolac, but dry mouth was significantly more common after the administration of tramadol than ketorolac (60% versus 27%). 7 Therefore, we conducted the study to assess tramadol's effectiveness and tolerability as an analgesic in comparison with the currently widely used NSAID in acute musculoskeletal pain in the emergency setting. Rosenthal showed that combination therapy had promising result. 8 Tramadol/paracetamol add-on therapy effectively managed painful osteoarthritis flare in the elderly subset and was generally well tolerated. We chose combinations of paracetamol with the study drugs to maximise the analgesic effects and minimise side effects.
In our study, we found that the intramuscular tramadol and oral paracetamol combination had statistically significantly better analgesic effect than the ketorolac and paracetamol combination at 60 minutes after injection. However, we could not show any significant clinical difference as measured by patients' satisfaction, reduction in admission rate, and the use of rescue drugs. This could be due to the short study period and rapid follow up assessment after one single treatment as compared to the other studies, which were done in hospitalised patients. Also, the synergistic effect of paracetamol could have blunted the significance. Moreover, the sample size was calculated from the effect size of the change in VAS, which might not be large enough with the power to detect any significant difference in the incidence of side effects and satisfaction score.
Our study, however, showed that intramuscular tramadol was safe to use. The commonest side effects of tramadol are minor: namely nausea, dizziness, drowsiness, sweating, vomiting and dry mouth. The reported incidence was about 1.6 to 6.1%. 4 Our study showed the incidence of side effects of the tramadol and paracetamol combination (48.7%) was higher than the ketorolac and paracetamol combination (43.6%), but it was not statistically significant. These minor effects were unexpectedly high compared to the reported incidence. However, only one patient needed treatment, which might reflect individual subjective variation and difference in reporting and recording symptoms. The tramadol and paracetamol combination had more nausea than the ketorolac and paracetamol combination. There was no seizure or psychotic effects like mania, auditory hallucination and serotonin syndrome in our patients.
The cost per treatment of tramadol (100 mg per ampoule) was HK$2.37 and the cost of ketorolac (30 mg per ampoule) was HK$7.50 per treatment. Hence, the cost of tramadol was HK$5.13 or 68.4% less than ketorolac.
The limitation of our study was the small sample size. However, the sample size was calculated beforehand with a usual accepted significance, and the difference in analgesia was shown to be statistically significant. Randomising patients by drawing from equal preset numbers of envelopes could cause randomisation error, but the characteristics of the patients in both groups were still comparable.
Despite the limitations, our study showed that intramuscular tramadol and oral paracetamol was as effective as NSAID in the treatment of moderate to severe acute musculoskeletal and arthritic pain. In addition, it may have less severe side effects and is cheaper. Further studies are needed to demonstrate its effectiveness in specific disease entities like arthritic pain and to assess its effect after repeated dosages and after a longer period.
Conclusion
Our study showed intramuscular tramadol and oral paracetamol combination therapy was effective and safe to use in acute pain management. Though many patients experienced side effects, all of them were minor. Patients in the tramadol group experienced significantly more nausea, but no major adverse event occurred. An intramuscular tramadol and oral paracetamol combination is appropriate as first line analgesic in acute musculoskeletal pain control in the emergency department. However, the effect of long term repeated use of intramuscular tramadol has to be monitored. The adverse events need to be reported and documented.
